Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
650
mi
from 43215
Haverhill, MA
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
650
mi
from 43215
Haverhill, MA
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
564
mi
from 43215
Springfield, MA
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
564
mi
from 43215
Springfield, MA
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
208
mi
from 43215
Kalamazoo, MI
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
208
mi
from 43215
Kalamazoo, MI
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
625
mi
from 43215
Minneapolis, MN
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
625
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from 43215
South Haven, MS
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from 43215
South Haven, MS
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1464
mi
from 43215
Bozeman, MT
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1464
mi
from 43215
Bozeman, MT
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
718
mi
from 43215
Lincoln, NE
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
718
mi
from 43215
Lincoln, NE
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
486
mi
from 43215
Bronx, NY
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
486
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
492
mi
from 43215
Lake Success, NY
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
492
mi
from 43215
Lake Success, NY
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
523
mi
from 43215
Potsdam, NY
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
523
mi
from 43215
Potsdam, NY
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
306
mi
from 43215
Hickory, NC
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
306
mi
from 43215
Hickory, NC
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2024
mi
from 43215
Oregon City, OR
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2024
mi
from 43215
Oregon City, OR
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis
2028
mi
from 43215
Portland, OR
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis
2028
mi
from 43215
Portland, OR
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
323
mi
from 43215
Camp Hill, PA
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
323
mi
from 43215
Camp Hill, PA
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
363
mi
from 43215
Simpsonville, SC
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
363
mi
from 43215
Simpsonville, SC
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
1065
mi
from 43215
Austin, TX
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
1065
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
885
mi
from 43215
McKinney, TX
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
885
mi
from 43215
McKinney, TX
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
868
mi
from 43215
Sherman, TX
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
868
mi
from 43215
Sherman, TX
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
863
mi
from 43215
Tyler, TX
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
863
mi
from 43215
Tyler, TX
Click here to add this to my saved trials
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
335
mi
from 43215
Midlothian, VA
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
335
mi
from 43215
Midlothian, VA
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
409
mi
from 43215
Fort Payne, AL
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
409
mi
from 43215
Fort Payne, AL
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1979
mi
from 43215
Beverly Hills, CA
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1979
mi
from 43215
Beverly Hills, CA
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2046
mi
from 43215
Stockton, CA
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2046
mi
from 43215
Stockton, CA
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1991
mi
from 43215
West Hills, CA
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1991
mi
from 43215
West Hills, CA
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
992
mi
from 43215
Doral, FL
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
992
mi
from 43215
Doral, FL
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
769
mi
from 43215
Inverness, FL
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
769
mi
from 43215
Inverness, FL
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
746
mi
from 43215
Ormond Beach, FL
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
746
mi
from 43215
Ormond Beach, FL
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
758
mi
from 43215
Port Orange, FL
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
758
mi
from 43215
Port Orange, FL
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
340
mi
from 43215
Lutherville, MD
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
340
mi
from 43215
Lutherville, MD
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
473
mi
from 43215
Ridgewood, NJ
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
473
mi
from 43215
Ridgewood, NJ
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
427
mi
from 43215
Columbia, SC
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
427
mi
from 43215
Columbia, SC
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
360
mi
from 43215
Greenville, SC
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
360
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
382
mi
from 43215
Lancaster, SC
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
382
mi
from 43215
Lancaster, SC
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
892
mi
from 43215
Allen, TX
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
892
mi
from 43215
Allen, TX
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1108
mi
from 43215
New Braunfels, TX
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1108
mi
from 43215
New Braunfels, TX
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1092
mi
from 43215
San Marcos, TX
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1092
mi
from 43215
San Marcos, TX
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
868
mi
from 43215
Sherman, TX
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
868
mi
from 43215
Sherman, TX
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
984
mi
from 43215
Tomball, TX
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
984
mi
from 43215
Tomball, TX
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
335
mi
from 43215
Midlothian, VA
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
335
mi
from 43215
Midlothian, VA
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2013
mi
from 43215
Tacoma, WA
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2013
mi
from 43215
Tacoma, WA
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
457
mi
from 43215
East Brunswick, NJ
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
457
mi
from 43215
East Brunswick, NJ
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis
1139
mi
from 43215
San Antonio, TX
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis
1139
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
885
mi
from 43215
McKinney, TX
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Jection Fraction (AWAKE-HF).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
885
mi
from 43215
McKinney, TX
Click here to add this to my saved trials
Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology
Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology
Status: Enrolling
Updated:  12/31/1969
Stanford University
2100
mi
from 43215
Stanford, CA
Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology
Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology
Status: Enrolling
Updated: 12/31/1969
Stanford University
2100
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Understanding the Mechanisms of Diastolic Dysfunction
A New Framework for Understanding the Mechanism of Diastolic Dysfunction
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
1982
mi
from 43215
Los Angeles, CA
Understanding the Mechanisms of Diastolic Dysfunction
A New Framework for Understanding the Mechanism of Diastolic Dysfunction
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
1982
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Lidocaine as an Endotracheal Tube (ETT) Cuff Media
Lidocaine as an ETT Cuff Media in the Immediate Post-operative Cardiac Surgery Patient Population, and Its Effect on Sedation/Analgesia Requirements: a Pilot Study
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Lidocaine as an Endotracheal Tube (ETT) Cuff Media
Lidocaine as an ETT Cuff Media in the Immediate Post-operative Cardiac Surgery Patient Population, and Its Effect on Sedation/Analgesia Requirements: a Pilot Study
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Text Message Intervention to Improve Cardiac Rehab Participation
Text Messaging to Improve Heart Healthy Behaviors and Cardiac Rehabilitation Participation
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
2005
mi
from 43215
Seattle, WA
Text Message Intervention to Improve Cardiac Rehab Participation
Text Messaging to Improve Heart Healthy Behaviors and Cardiac Rehabilitation Participation
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
2005
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
A Phase 2 Open-Label Study of EN3835 In The Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #1
1651
mi
from 43215
Scottsdale, AZ
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
A Phase 2 Open-Label Study of EN3835 In The Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #1
1651
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
A Phase 2 Open-Label Study of EN3835 In The Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #2
mi
from 43215
Huntington Beach, CA
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
A Phase 2 Open-Label Study of EN3835 In The Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #2
mi
from 43215
Huntington Beach, CA
Click here to add this to my saved trials
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
A Phase 2 Open-Label Study of EN3835 In The Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #3
1951
mi
from 43215
San Diego, CA
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
A Phase 2 Open-Label Study of EN3835 In The Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #3
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials